Observatory of Patients With MyeloProliferative Neoplasm Treated With Anti-inflammatory Immunotherapy

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06476535

Acronym

OPIUM

Enrollment

100

Registered

2024-06-26

Start date

2024-06-11

Completion date

2026-05-31

Last updated

2024-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammatory Disease, Myeloproliferative Neoplasm

Brief summary

The study will collect cases of MPN patients who also benefit from an anti-inflammatory immunotherapy for another disease. Efficacy and tolerability of the drug will be assessed in this population.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* MyeloProliferative Neoplasm diagnosis * receiving or having received an immunotherapy targeting IL-1, IL-6, IL-17, IL-23 or TNF

Exclusion criteria

* Unable to consent

Design outcomes

Primary

Measure	Time frame	Description
Efficacy of the anti-inflammatory immunotherapy	1 year	Depending on the indication of the anti-inflammatory treatment, clinical efficacy will be assessed clinically as number of patients reaching complete (total disappearance of initial symptoms- diarrhea, arthritis, fever, skin lesions), partial (improvement of symptoms, but not total disappearance) or absence of response (the treatment did not improve the symptoms). Clinical judgement will be according to the physician appreciation.
Tolerability of the anti-inflammatory immunotherapy	1 year	Tolerability will be assessed as the number of reported unexpected side effects attributed to the treatment as judged by the caring physician, including treatment discontinuation

Countries

France

Outcome results